Serum Cystatin C as a Biomarker for Early Diabetic Kidney Disease and Dyslipidemia in Young Type 1 Diabetes Patients
<i>Background and objectives:</i> This study aimed to assess the clinical significance of serum cystatin C in the early diagnosis of renal injury and its association with dyslipidemia in young T1D patients. <i>Materials and Methods:</i> A total of 779 subjects were evaluated...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-02-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1648-9144/58/2/218 |
| _version_ | 1797478280094285824 |
|---|---|
| author | Ingrida Stankute Lina Radzeviciene Ausra Monstaviciene Rimante Dobrovolskiene Evalda Danyte Rasa Verkauskiene |
| author_facet | Ingrida Stankute Lina Radzeviciene Ausra Monstaviciene Rimante Dobrovolskiene Evalda Danyte Rasa Verkauskiene |
| author_sort | Ingrida Stankute |
| collection | DOAJ |
| description | <i>Background and objectives:</i> This study aimed to assess the clinical significance of serum cystatin C in the early diagnosis of renal injury and its association with dyslipidemia in young T1D patients. <i>Materials and Methods:</i> A total of 779 subjects were evaluated for kidney function by estimating glomerular filtration rate (eGFR) based on serum creatinine (eGFRcreat) and cystatin C (eGFRcys). <i>Results:</i> The median age of study subjects was 16.2 years (2.1;26.4), diabetes duration—5.3 years (0.51;24.0). The median of HbA1c was 8% (5.2;19.9) (64 mmol/mol (33.3;194)); 24.2% of participants had HbA1c < 7% (53 mmol/mol). Elevated albumin excretion rate was found in 13.5% of subjects. The median of cystatin C was 0.8 mg/L (0.33;1.71), the median of creatinine—63 µmol/L (6;126). The median of eGFRcys was lower than eGFRcreat (92 mL/min/1.73 m<sup>2</sup> vs. 101 mL/min/1.73 m<sup>2</sup>, <i>p</i> < 0.001). A total of 30.2% of all patients were classified as having worse kidney function when using cystatin C vs. creatinine for eGFR calculation. Linear correlations were found between cystatin C and HbA1c, r = −0.088, <i>p</i> < 0.05, as well as cystatin C and HDL, r = −0.097, <i>p</i> < 0.01. <i>Conclusions:</i> This study showed that cystatin C might be used as an additional biomarker of early kidney injury in young patients with T1D. |
| first_indexed | 2024-03-09T21:29:41Z |
| format | Article |
| id | doaj.art-915e5679aa8d437d8dd9cb010a5a17f2 |
| institution | Directory Open Access Journal |
| issn | 1010-660X 1648-9144 |
| language | English |
| last_indexed | 2024-03-09T21:29:41Z |
| publishDate | 2022-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj.art-915e5679aa8d437d8dd9cb010a5a17f22023-11-23T20:59:52ZengMDPI AGMedicina1010-660X1648-91442022-02-0158221810.3390/medicina58020218Serum Cystatin C as a Biomarker for Early Diabetic Kidney Disease and Dyslipidemia in Young Type 1 Diabetes PatientsIngrida Stankute0Lina Radzeviciene1Ausra Monstaviciene2Rimante Dobrovolskiene3Evalda Danyte4Rasa Verkauskiene5Institute of Endocrinology, Lithuanian University of Health Sciences, Eiveniu 2, LT-50009 Kaunas, LithuaniaInstitute of Endocrinology, Lithuanian University of Health Sciences, Eiveniu 2, LT-50009 Kaunas, LithuaniaMedical Academy, Lithuanian University of Health Sciences, Eiveniu 2, LT-50161 Kaunas, LithuaniaMedical Academy, Lithuanian University of Health Sciences, Eiveniu 2, LT-50161 Kaunas, LithuaniaInstitute of Endocrinology, Lithuanian University of Health Sciences, Eiveniu 2, LT-50009 Kaunas, LithuaniaInstitute of Endocrinology, Lithuanian University of Health Sciences, Eiveniu 2, LT-50009 Kaunas, Lithuania<i>Background and objectives:</i> This study aimed to assess the clinical significance of serum cystatin C in the early diagnosis of renal injury and its association with dyslipidemia in young T1D patients. <i>Materials and Methods:</i> A total of 779 subjects were evaluated for kidney function by estimating glomerular filtration rate (eGFR) based on serum creatinine (eGFRcreat) and cystatin C (eGFRcys). <i>Results:</i> The median age of study subjects was 16.2 years (2.1;26.4), diabetes duration—5.3 years (0.51;24.0). The median of HbA1c was 8% (5.2;19.9) (64 mmol/mol (33.3;194)); 24.2% of participants had HbA1c < 7% (53 mmol/mol). Elevated albumin excretion rate was found in 13.5% of subjects. The median of cystatin C was 0.8 mg/L (0.33;1.71), the median of creatinine—63 µmol/L (6;126). The median of eGFRcys was lower than eGFRcreat (92 mL/min/1.73 m<sup>2</sup> vs. 101 mL/min/1.73 m<sup>2</sup>, <i>p</i> < 0.001). A total of 30.2% of all patients were classified as having worse kidney function when using cystatin C vs. creatinine for eGFR calculation. Linear correlations were found between cystatin C and HbA1c, r = −0.088, <i>p</i> < 0.05, as well as cystatin C and HDL, r = −0.097, <i>p</i> < 0.01. <i>Conclusions:</i> This study showed that cystatin C might be used as an additional biomarker of early kidney injury in young patients with T1D.https://www.mdpi.com/1648-9144/58/2/218cystatin Ctype 1 diabetesmicrovascular complicationdyslipidemiayouth |
| spellingShingle | Ingrida Stankute Lina Radzeviciene Ausra Monstaviciene Rimante Dobrovolskiene Evalda Danyte Rasa Verkauskiene Serum Cystatin C as a Biomarker for Early Diabetic Kidney Disease and Dyslipidemia in Young Type 1 Diabetes Patients Medicina cystatin C type 1 diabetes microvascular complication dyslipidemia youth |
| title | Serum Cystatin C as a Biomarker for Early Diabetic Kidney Disease and Dyslipidemia in Young Type 1 Diabetes Patients |
| title_full | Serum Cystatin C as a Biomarker for Early Diabetic Kidney Disease and Dyslipidemia in Young Type 1 Diabetes Patients |
| title_fullStr | Serum Cystatin C as a Biomarker for Early Diabetic Kidney Disease and Dyslipidemia in Young Type 1 Diabetes Patients |
| title_full_unstemmed | Serum Cystatin C as a Biomarker for Early Diabetic Kidney Disease and Dyslipidemia in Young Type 1 Diabetes Patients |
| title_short | Serum Cystatin C as a Biomarker for Early Diabetic Kidney Disease and Dyslipidemia in Young Type 1 Diabetes Patients |
| title_sort | serum cystatin c as a biomarker for early diabetic kidney disease and dyslipidemia in young type 1 diabetes patients |
| topic | cystatin C type 1 diabetes microvascular complication dyslipidemia youth |
| url | https://www.mdpi.com/1648-9144/58/2/218 |
| work_keys_str_mv | AT ingridastankute serumcystatincasabiomarkerforearlydiabetickidneydiseaseanddyslipidemiainyoungtype1diabetespatients AT linaradzeviciene serumcystatincasabiomarkerforearlydiabetickidneydiseaseanddyslipidemiainyoungtype1diabetespatients AT ausramonstaviciene serumcystatincasabiomarkerforearlydiabetickidneydiseaseanddyslipidemiainyoungtype1diabetespatients AT rimantedobrovolskiene serumcystatincasabiomarkerforearlydiabetickidneydiseaseanddyslipidemiainyoungtype1diabetespatients AT evaldadanyte serumcystatincasabiomarkerforearlydiabetickidneydiseaseanddyslipidemiainyoungtype1diabetespatients AT rasaverkauskiene serumcystatincasabiomarkerforearlydiabetickidneydiseaseanddyslipidemiainyoungtype1diabetespatients |